Literature DB >> 21597297

Rapamycin-induced impaired wound healing is associated with compromised tissue lactate accumulation and extracellular matrix remodeling.

J Weinreich1, S Löb, M Löffler, I Königsrainer, D Zieker, A Königsrainer, S Coerper, S Beckert.   

Abstract

INTRODUCTION: Extracellular matrix (ECM) remodeling involving matrix metalloproteinases (MMPs) and wound lactate accumulation are essential elements of tissue repair. The aim of this study was to investigate whether rapamycin-induced impaired healing is associated with compromised wound fluid lactate accumulation and altered ECM remodeling.
METHODS: Polyvinyl alcohol sponges were subcutaneously implanted in male C57/BL6 mice. Animals were randomized to daily intraperitoneal treatment with either vehicle or 1.5 mg/kg rapamycin. After 7 or 14 days, sponges were harvested to collect wound fluid for subsequent analyses. Wounds were excised for assessment of tensile strength.
RESULTS: After 7 days, wound hydroxyproline content was significantly decreased due to rapamycin therapy, whereas the observed difference in tensile strength marginally failed to show statistical significance. In addition, rapamycin reduced wound lactate accumulation and enhanced MMP-2 protein expression, and both MMP-2 and MMP-9 activity. At day 14, wound tensile strength and hydroxyproline content were significantly lower along with an increase in MMP-2 and MMP-9 activity in rapamycin-treated mice. Similarly, wound fluid lactate concentration and MMP-2 protein expression were found to be persistently decreased and increased, respectively.
CONCLUSIONS: Rapamycin affects tissue repair by interfering with fundamental mechanisms involved in healing, namely lactate accumulation and ECM remodeling.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21597297     DOI: 10.1159/000327972

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  4 in total

1.  A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.

Authors:  Silvan R Urfer; Tammi L Kaeberlein; Susan Mailheau; Philip J Bergman; Kate E Creevy; Daniel E L Promislow; Matt Kaeberlein
Journal:  Geroscience       Date:  2017-04-03       Impact factor: 7.713

2.  [Delayed wound healing during therapy of cutaneous graft-versus-host disease with everolimus].

Authors:  A Brown; D Neumayer; Z Rafieé-Tari; T Krieg; S A Eming
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

3.  Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain.

Authors:  Michael S Hester; Bethany E Hosford; Victor R Santos; Shatrunjai P Singh; Isaiah J Rolle; Candi L LaSarge; John P Liska; Norberto Garcia-Cairasco; Steve C Danzer
Journal:  Exp Neurol       Date:  2016-03-17       Impact factor: 5.330

4.  Delivery of Rapamycin Using In Situ Forming Implants Promotes Immunoregulation and Vascularized Composite Allograft Survival.

Authors:  Damian Sutter; Dzhuliya V Dzhonova; Jean-Christophe Prost; Cedric Bovet; Yara Banz; Lisa Rahnfeld; Jean-Christophe Leroux; Robert Rieben; Esther Vögelin; Jan A Plock; Paola Luciani; Adriano Taddeo; Jonas T Schnider
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.